Respirerx Pharmaceuticals Inc (OP: RSPI )

0.0006 -0.0009 (-60.00%)

Streaming Delayed Price Updated: 3:13 PM EST, Nov 8, 2024 Add to My Watchlist

Price and Volume

Volume	200
Open	0.0006
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.0015
Today's Range	0.0006 - 0.0006
52wk Range	0.0002 - 0.0069
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Stocks Under 1¢: June 2024 Gains, July 2024 Watchlist SMCE, SPZI, RSPI, HALB, BIEI, RJDG

July 03, 2024

Via AB Newswire

RespireRx Transferes Its Pharmaceutical Cannabinoid Program To ResolutionRx

August 09, 2023

RespireRx Pharmaceuticals Inc. (OTCPK:RSPI), focused on the discovery and development of treatments to combat diseases caused by disruption of neuronal signaling, and ResolutionRx Ltd, an unlisted...

Via Benzinga

Performance

YTD	-33.33%	-33.33%
1 Month	-53.85%	-53.85%
3 Month	+50.00%	+50.00%
6 Month	-40.00%	-40.00%
1 Year	-33.33%	-33.33%

More News

RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development

December 05, 2022

From RespireRX Pharmaceuticals Inc.

Via GlobeNewswire

RespireRx Signs LOI With Australian CRO For Dronabinol Development For Obstructive Sleep Apnea

November 17, 2022

Via Benzinga

RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Obstructive Sleep Apnea

November 17, 2022

From RespireRX Pharmaceuticals Inc.

Via GlobeNewswire

RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4

November 10, 2022

From RespireRX Pharmaceuticals Inc.

Via GlobeNewswire

RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa Is an Invited Speaker at the 5th Meridian Drug Discovery Summit

November 07, 2022

From RespireRX Pharmaceuticals Inc.

Via GlobeNewswire

RespireRx Pharmaceuticals Files Patent: Claims To Improve Solubility & Bioavailability Of Cannabinoids

March 24, 2022

Via Benzinga

Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday

December 14, 2021

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.